Marta Laganà

ORCID: 0000-0001-8457-122X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Adrenal and Paraganglionic Tumors
  • Cancer, Hypoxia, and Metabolism
  • Glioma Diagnosis and Treatment
  • Pituitary Gland Disorders and Treatments
  • Bone health and treatments
  • Bone health and osteoporosis research
  • Hormonal Regulation and Hypertension
  • Bone Metabolism and Diseases
  • Nutrition and Health in Aging
  • Advanced Breast Cancer Therapies
  • Prostate Cancer Treatment and Research
  • Lung Cancer Research Studies
  • COVID-19 and healthcare impacts
  • Cancer Immunotherapy and Biomarkers
  • HER2/EGFR in Cancer Research
  • Neuroendocrine Tumor Research Advances
  • Cancer Risks and Factors
  • Nutritional Studies and Diet
  • Cervical Cancer and HPV Research
  • Intraperitoneal and Appendiceal Malignancies
  • Poxvirus research and outbreaks
  • Patient Dignity and Privacy
  • Bacillus and Francisella bacterial research
  • Plant and Fungal Interactions Research
  • Lung Cancer Treatments and Mutations

University of Brescia
2018-2024

Surgical Specialties (Canada)
2024

Brescia University
2024

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2019-2024

The University of Texas MD Anderson Cancer Center
2024

Inserm
2021-2024

Université Paris-Saclay
2021-2024

Institut thématique Immunologie, inflammation, infectiologie et microbiologie
2023

Inflammation, Microbiome and Immunosurveillance
2021

Université Paris-Sud
2021

Adrenocortical carcinoma (ACC) has an aggressive but variable clinical course. Prognostic stratification based on the European Network for Study of Adrenal Tumours stage and Ki67 index is limited. We aimed to demonstrate prognostic role a points-based score (S-GRAS) in large cohort patients with ACC.This multicentre, retrospective study ACC who underwent adrenalectomy.The S-GRAS was calculated as sum following points: tumour (1-2 = 0; 3 1; 4 2), grade (Ki67 0-9% 10-19% ≥20% 2 points),...

10.1530/eje-21-0510 article EN European Journal of Endocrinology 2021-10-28

Abstract Context Because of the rarity adrenocortical cancer (ACC), only a few population-based studies are available, and they reported limited details in characterization patients their treatment. Objective To describe nationwide cohort presentation with ACC, treatment strategies, potential prognostic factors. Methods Retrospective analysis 512 diagnosed 12 referral centers Italy from January 1990 to June 2018. Results ACC as incidentalomas accounted for overall 38.1% cases, frequency that...

10.1210/clinem/dgad199 article EN The Journal of Clinical Endocrinology & Metabolism 2023-04-06

International guidelines recommend local therapies (LTs) such as thermal ablation (LTA; radiofrequency, microwave, cryoablation), transarterial (chemo)embolisation (TA(C)E), and radioembolisation (TARE) therapeutic options for advanced adrenocortical carcinoma (ACC). However, the evidence these recommendations is scarce. We retrospectively analysed patients receiving LTs ACC. Time to progression of treated lesion (tTTP) was primary endpoint. The secondary endpoints were best objective...

10.3390/cancers16040706 article EN Cancers 2024-02-07

Etoposide, doxorubicin and cisplatin plus oral mitotane (EDP-M) comprise the reference regimen in management of patients with adrenocortical carcinoma (ACC). In this paper, we described outcome 58 advanced/metastatic ACC consecutively treated EDP-M a center for rare disease Italy. series, obtained partial response 50% patients; median progression free survival (PFS) overall were 10.1 months (95% Confidence Interval [CI 95%] 8.1–12.8) 18.7 CI: 14.6–22.8), respectively. was not interrupted...

10.3390/cancers12040941 article EN Cancers 2020-04-10

Background . Trastuzumab emtansine (T-DM1), sacituzumab govitecan (SG), and trastuzumab deruxtecan (T-DXd) are three ADCs approved for the treatment of metastatic breast cancer (MBC). Since gastrointestinal toxicities have been commonly observed with these drugs in clinical trials, a pooled analysis evaluating adverse events (AEs) patients MBC treated trials was performed. Methods PubMed, Embase, Cochrane Library were searched from inception until May 2023 phase II III reporting frequency...

10.1016/j.clbc.2024.04.003 article EN cc-by-nc-nd Clinical Breast Cancer 2024-04-08

Objective Temozolomide has shown a significant anti-proliferative activity on adrenocortical cancer (ACC) cells in vitro . Design On the basis of these results drug was prescribed as second/third line advanced metastatic ACC patients four referral centers Italy. Methods We retrospectively collected anagraphic, clinical and pathological data with disease progression to standard chemotherapy plus mitotane who were treated temozolomide at dose 200 mg/m 2 /die given for 5 consecutive days every...

10.1530/eje-19-0570 article EN European Journal of Endocrinology 2019-10-22

Abstract Context We investigated the role of Gallium 68 dodecanetetraacetic acid Tyr3-octreotide (68Ga-DOTATOC) positron emission tomography/computed tomography (PET/CT) in detecting somatostatin receptors (SSTRs) 19 patients with metastatic adrenocortical carcinoma (ACC) and explored activity yttrium-90/lutetium-177 (90Y/177Lu-DOTATOC) peptide receptor radionuclide therapy (PRRT). Case description methods 68Ga uptake sites was scored terms intensity anatomical distribution standard value...

10.1210/clinem/dgz091 article EN The Journal of Clinical Endocrinology & Metabolism 2019-10-06

Importance Women with early breast cancer (EBC) exposed to aromatase inhibitors (AIs) may experience fragility fractures despite treatment bone-active drugs. Risk factors for in patients receiving AIs and denosumab have not been explored date. Objectives To evaluate whether an association exists between dual x-ray absorptiometry (DXA)–measured fat body mass (FBM) vertebral fracture (VF) progression postmenopausal women EBC undergoing adjuvant therapy combination examine VF was associated...

10.1001/jamanetworkopen.2023.50950 article EN cc-by-nc-nd JAMA Network Open 2024-01-10

Triple-negative breast cancer (TNBC) is an aggressive subtype, owing to its high metastatic potential: Patients who develop brain metastases (BMs) have a poor prognosis due the lack of effective systemic treatments. Surgery and radiation therapy are valid options, while pharmacotherapy still relies on chemotherapy, which has limited efficacy. Among new treatment strategies available, antibody-drug conjugate (ADC) sacituzumab govitecan shown encouraging activity in TNBC, even presence BMs.A...

10.3389/fonc.2023.1139372 article EN cc-by Frontiers in Oncology 2023-02-20

Adrenocortical cancer (ACC) is a rare malignancy with dismal prognosis. The treatment includes mitotane and EDP chemotherapy (etoposide, doxorubicin, cisplatin). However, new therapeutic approaches for advanced ACC are needed, particularly targeting the metastatic process. Here, we deepen role of progesterone as potential drug ACC, in line its antitumoral effect other cancers.NCI-H295R, MUC-1, TVBF-7 cell lines were used xenografted zebrafish embryos. Migration invasion studied using...

10.3390/ijms24076829 article EN International Journal of Molecular Sciences 2023-04-06

Human papillomaviruses (HPVs) are commensal viruses with pathogenic potential. Their life cycle requires the proliferation and differentiation of keratinocytes (KCs) to form pluristratified epithelia. Based on original organotypic epithelial raft cultures protocol, we provide an updated workflow optimally generate human epithelia supporting complete HPV replicative cycle, here called 3D full-thickness (3Deps). We describe steps for genome preparation, KC transfection, dermal equivalent...

10.1016/j.xpro.2023.102828 article EN cc-by-nc-nd STAR Protocols 2024-01-21

Introduction Adrenocortical carcinoma (ACC) is a rare cancer that commonly spreads to the liver, lungs and lymph nodes. Bone metastases are infrequent. Objective The aim of this report was describe clinical characteristics, survival perspective, prognostic factors frequency adverse skeletal-related events (SREs) in patients with ACC who developed bone metastasis. Methods This retrospective, observational, multicenter, multinational study diagnosed from were treated followed up three European...

10.1530/eje-19-0026 article EN European Journal of Endocrinology 2019-04-10

The prevalence of Skeletal Related Adverse Events (SREs) in EGFR mutated non-small cell lung cancer (NSCLC) patients with bone metastases, treated modern tyrosine kinase inhibitors (TKIs), has been scarcely investigated.We retrospectively evaluated the data NSCLC metastases TKIs 12 Italian centers from 2014 to 2019, primary aim explore type and frequency SREs.Seventy-seven out 274 enrolled (28%) developed at least one major SRE: 55/274 (20%) fractures, 30/274 (11%) spinal cord compression,...

10.3389/fonc.2020.588862 article EN cc-by Frontiers in Oncology 2020-11-12

Mitotane is the only drug approved for treatment of adrenocortical carcinoma (ACC). The regimen to be added mitotane a chemotherapy including etoposide, doxorubicin, and cisplatin. This pharmacological approach, however, has limited efficacy significant toxicity. Evidence indicates that ACC seems sensitive alkylating agents. Trabectedin an anti-tumor acts as agent with complex mechanism action. Here, we investigated whether trabectedin could exert cytotoxic activity in vitro cell models ACC....

10.3390/cancers12040928 article EN Cancers 2020-04-09

•Cabazitaxel is well tolerated but poorly active as second/third-line treatment in patients with advanced ACC.•Combining RECIST and Choi criteria could be of value the assessment disease response to chemotherapy ACC patients.•Older age, elevated cortisol LDH blood level correlate a greater risk death multivariate analysis. BackgroundAdrenocortical carcinoma (ACC) rare aggressive malignancy poor prognosis. No efficacious options are currently available for metastatic progression standard...

10.1016/j.esmoop.2022.100422 article EN cc-by-nc-nd ESMO Open 2022-03-07

Mitotane is the cornerstone of medical treatment adrenocortical carcinoma. Estrogenic-like side effects frequently occur in patients, and previous studies explored chemical nature interaction between estrogen receptor-α (ER-α) toxic compounds, including DDD derivatives. We used molecular docking dynamics (MD) simulations to explore possible mitotane ER-α receptor induced conformational changes. The expressing MCF-7 cells were exposed with/without tamoxifen, cell viability/proliferation was...

10.3390/biomedicines9060681 article EN cc-by Biomedicines 2021-06-16

Human papillomaviruses (HPVs) are highly prevalent commensal viruses that require epithelial stratification to complete their replicative cycle. While HPV infections most often asymptomatic, certain types can cause lesions, usually benign. In rare cases, these may progress non-replicative viral cycles associated with high oncogene expression promoting cell transformation, and eventually cancer when not cleared by host responses. the consequences of HPV-induced transformation on keratinocytes...

10.3389/fcimb.2023.1138232 article EN cc-by Frontiers in Cellular and Infection Microbiology 2023-05-16
Coming Soon ...